ahlam1399
09-14-2015, 11:18 AM
Sa**fi?s combination diabetes drug hits goal in second late-stage trial
PARIS (Reuters) - Sa**fi said on Monday a second late-stage Phase III study of its LixiLan diabetes drug had met its main target, readying it for regulatory submissions by the fourth quarter in the United States and the first quarter of next year in the European Union.
http://rc.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/rc/1/rc.img (http://rc.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/rc/1/rc.htm)
http://rc.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/rc/2/rc.img (http://rc.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/rc/2/rc.htm)
http://rc.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/rc/3/rc.img (http://rc.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/rc/3/rc.htm)
http://da.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/a2.img (http://da.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/a2.htm)
http://adchoice.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/ach.img (http://adchoice.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/ach.htm)http://pi.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/a2t.imghttp://pi2.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/49d26162/sc/35/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=9tKXi-oOE**:C1zApBOocDI:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=9tKXi-oOE**:C1zApBOocDI:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=9tKXi-oOE**:C1zApBOocDI:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=9tKXi-oOE**:C1zApBOocDI:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=9tKXi-oOE**:C1zApBOocDI:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/9tKXi-oOE**
PARIS (Reuters) - Sa**fi said on Monday a second late-stage Phase III study of its LixiLan diabetes drug had met its main target, readying it for regulatory submissions by the fourth quarter in the United States and the first quarter of next year in the European Union.
http://rc.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/rc/1/rc.img (http://rc.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/rc/1/rc.htm)
http://rc.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/rc/2/rc.img (http://rc.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/rc/2/rc.htm)
http://rc.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/rc/3/rc.img (http://rc.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/rc/3/rc.htm)
http://da.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/a2.img (http://da.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/a2.htm)
http://adchoice.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/ach.img (http://adchoice.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/ach.htm)http://pi.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/a2t.imghttp://pi2.feedsportal.com/r/238385767259/u/49/f/654207/c/35217/s/49d26162/sc/35/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/49d26162/sc/35/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=9tKXi-oOE**:C1zApBOocDI:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=9tKXi-oOE**:C1zApBOocDI:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=9tKXi-oOE**:C1zApBOocDI:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=9tKXi-oOE**:C1zApBOocDI:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=9tKXi-oOE**:C1zApBOocDI:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/9tKXi-oOE**